Summary of IMDX Q2 2026 Earnings Call

1Key Financial Results and Metrics

Adjusted EBITDA Loss: Narrowed to $7.8 million in Q2 2026, down from previous peaks.

Cash Burn: $10 million in Q2, expected to average $8 million per quarter for the second half of the year, higher than prior expectations of $6 million.

Revenue Expectations: Modest revenue anticipated in the second half from laboratory services, research use-only kit sales, and GraftAssureCore.

2Strategic Updates and Business Highlights

FDA Marketing Authorization: The company is optimistic about receiving FDA marketing authorization for GraftAssureDx later in 2026, following a productive engagement with the FDA.

Market Landscape: Improved conditions for transplant rejection tests due to expanded Medicare reimbursement guidelines, increasing the potential for GraftAssureDx's commercial success.

Competitive Position: IMDX claims to be approximately two years ahead of competitors in kitted product development.

Customer Engagement: Over half of the top 10 transplant centers in the U.S. are engaged with IMDX, indicating strong interest in their products.

Research and Development: Positive head-to-head data comparing their assay favorably against competitors, enhancing interest from potential customers.

3Forward Guidance and Outlook

Revenue Growth: The company plans to align future investments with expected revenue growth, aiming for breakeven and eventual profitability.

Total Addressable Market (TAM): The TAM for kitted transplant organ testing is projected to exceed $2 billion, with potential for growth through increased testing frequency and expanded organ indications.

European Market: Preparations for IVDR submission are on track, with expectations for a smoother process compared to FDA.

4Bad News, Challenges, or Points of Concern

Cash Burn Increase: The anticipated cash burn is higher than previously expected, raising concerns about financial runway.

Regulatory Risks: Delays in FDA authorization could push timelines into 2027, which may necessitate operational adjustments to extend cash runway.

Market Access in Europe: While there is optimism about market access, the European market remains in early stages, and broader adoption is contingent on reimbursement developments.

5Notable Q&A Insights

SIR Meeting with FDA: The upcoming meeting aims to ensure alignment with FDA requirements before submitting additional data for GraftAssureDx.

Registry Revenue: Accelerating enrollment in the registry is seen as a significant lever to offset revenue gaps.

Commercial Strategy with Bio-Rad: IMDX is exploring potential expansions of their partnership with Bio-Rad, which has been supportive throughout the FDA engagement process.

Utilization of Kits: The company is focused on how transplant centers will adopt the kits for surveillance testing, with ongoing discussions about optimal testing protocols.

Pricing Power: IMDX expects to maintain pricing power due to reimbursement structures and the lack of substitutes in the market. Overall, IMDX is positioned for potential growth with its upcoming product launch and favorable market conditions, but it faces challenges related to cash management and regulatory timelines.